Biotech IPOs are back and they are wearing cardiograms as accessories. Kardigan Inc. surged 27% on its trading debut after raising $400 million in its IPO, making it one of the more emphatic public market entrances for a heart-health focused biotech in recent memory. This lands the same week that Jeremy Grantham flagged a watershed moment for Big Tech, arguing that everyone is now battling on the same frontier, and that differentiation is nearly impossible when every player has access to the same tools. Kardigan, in that context, is interesting: it is differentiating not by technology but by organ.

The Cardiology Premium

Heart disease remains the leading cause of death in the United States, which means the total addressable market is essentially everyone who has ever had a heartbeat. The 27% pop suggests investors read Kardigan less as a specific therapeutic bet and more as a category claim: whoever wins cardiovascular health optimization at scale wins something enormous. This is the same logic driving AI infrastructure investment, bet on infrastructure, not on applications. where cardiovascular and metabolic bets are increasingly crowding the same term sheets.

Grantham's Watershed and the Differentiation Problem

Grantham's point about the frontier flattening is a useful corrective to IPO euphoria. When tools democratize, returns compress. Kardigan's pop is partly a liquidity event for early investors and partly a signal that public markets still have appetite for biotech narratives that feel concrete and personal. Your heart is not abstract. It does not require a whitepaper. In a market where AI companies struggle to explain what they actually do, 'we are fixing the heart' is a pitch with primordial clarity. Whether the science backs the story at $400 million is a separate question, one the market is, as usual, deferring.